InspireMD (STU:II2) Growth Rank: 1 (As of Aug. 03, 2026) — 83% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:II2 InspireMD Inc STU:II2
47 GF Score
Price €0.56
GF Value €1.48
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Growth Rank?

InspireMD STU:II2 -3.45% 47 Growth Rank is 1 as of Aug. 03, 2026, which is 83% below its 10-year median of 6.00. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.48 (Possible Value Trap). The stock has 3 warning signs investors should review.

InspireMD has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

STU:II2 vs TELA, BDMD, PAVM: Growth Rank Comparison

For the Medical Devices subindustry, InspireMD's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InspireMD Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Growth Rank distribution charts can be found below:

* The bar in red indicates where InspireMD's Growth Rank falls into.


STU:II2
47GF Score
InspireMD Inc STU:II2
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
InspireMD (STU:II2) has a Growth Rank of 1 as of Aug. 03, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on InspireMD and its competitors. This is 83% below median its historical median of 6.00. Over the past decade, InspireMD's Growth Rank has ranged from 1.00 to 7.00.
Is InspireMD's Growth Rank too high?
InspireMD's current Growth Rank of 1 is 83% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Growth Rank compare to TELA and BDMD?
InspireMD's Growth Rank of 1 can be compared against companies in the Medical Devices & Instruments industry. Historically, InspireMD's own Growth Rank has ranged from 1.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on InspireMD and its competitors. InspireMD's current Growth Rank is 1, which is 83% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.48, compared to a current price of €0.56 — trading 62.2% below its estimated fair value. The current Growth Rank is 1, which is 83% below median its 10-year median of 6.00. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For InspireMD (STU:II2), the current Growth Rank is 1 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.56 is trading 62.2% below its estimated GF Value™ of €1.48. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Growth Rank: 1 (83% below median its 10-year median of 6.00)
  • GF Value™: €1.48 vs. price of €0.56 (62.2% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score

Get the complete analysis for STU:II2

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.56
Price
€1.48
GF Value